Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 23 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

This development is expected to enhance the commercialization process of Desidustat in Greater China, according to the Managing Director of Zydus. Desidustat is marketed in India under the brand name Oxemia™ and is designed to improve treatment compliance for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 23, 2024, titled "New Drug Application of Zydus innovative drug Desidustat tablets by China Medical System Holdings Limited accepted in China".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases